Menu Search
Equities

Zevra Therapeutics Inc

ZVRA:NSQ

Zevra Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)9.53
  • Today's Change0.395 / 4.33%
  • Shares traded454.26k
  • 1 Year change+114.53%
  • Beta1.9717
Data delayed at least 15 minutes, as of Nov 22 2024 20:17 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Zevra Therapeutics Inc had net income fall 72.00% from a loss of 26.77m to a larger loss of 46.05m despite a 170.26% increase in revenues from 10.16m to 27.46m.
Gross margin53.72%
Net profit margin-342.63%
Operating margin-348.01%
Return on assets-51.39%
Return on equity-123.76%
Return on investment-61.91%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Zevra Therapeutics Inc fell by 22.42m. Cash Flow from Financing totalled 28.46m or 103.65% of revenues. In addition the company used 33.54m for operations while cash used for investing totalled 17.39m.
Cash flow per share-1.87
Price/Cash flow per share--
Book value per share1.31
Tangible book value per share-0.1041
More ▼

Balance sheet in USDView more

Zevra Therapeutics Inc has a Debt to Total Capital ratio of 45.78%, a lower figure than the previous year's 65.03%.
Current ratio2.88
Quick ratio--
Total debt/total equity0.8443
Total debt/total capital0.4578
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.